Nemocnice AGEL Novy Jicin a.s.
- Address
- lock Available on a paid plan
Immune System Diseases
At Nemocnice AGEL Novy Jicin a.s., investigators are advancing therapies for immune system diseases such as atopic dermatitis and related eczema, testing novel biologic agents to improve skin health and patient quality of life.
- Atopic Dermatitis
- Atopic Hand Eczema
- Moderate-to-severe Atopic Dermatitis
These studies evaluate safety and long‑term effectiveness of subcutaneous biologics compared with placebo, offering participants early access to potentially disease‑modifying treatments.
Neoplasms
The oncology program at Nemocnice AGEL Novy Jicin a.s. addresses a range of neoplasms, including kidney, prostate, endometrial, lung and ovarian cancers, by testing new immunotherapy combinations and targeted drugs aimed at extending survival.
- Advanced Clear Cell Renal Cell Carcinoma
- High‑Risk Localized Prostate Cancer
- Metastatic Castration‑Resistant Prostate Cancer
- Advanced or Recurrent Endometrial Cancer
- c‑Met Overexpressing Non‑Squamous NSCLC
- Platinum‑Sensitive Epithelial Ovarian Cancer
- Renal Cell Carcinoma Post‑Nephrectomy
Primary goals include measuring progression‑free and overall survival, providing patients with innovative options beyond standard care.
Skin and Connective Tissue Diseases
Research in skin and connective tissue diseases focuses on chronic conditions like atopic dermatitis and severe hand eczema, exploring next‑generation monoclonal antibodies to reduce disease activity.
- Atopic Dermatitis
- Atopic Hand Eczema
- Severe Atopic Dermatitis
Trials use validated severity indices to compare investigational agents with placebo, seeking to broaden therapeutic choices for individuals with persistent skin inflammation.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 15 therapeutic areas and 15 of 127 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 122 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1Pfizer Inc.4active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice AGEL Novy Jicin a.s.
lock Showing 1 of 72 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 127 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 14 | Unknown | 2022-04-01 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.